On May 20, 2019 Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, reported that an abstract describing clinical data regarding their lysine-specific demethylase (LSD1) inhibitor has been selected for an oral presentation at the 24th Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) to be held in Amsterdam, The Netherlands from June 13-16, 2019 (Press release, Imago BioSciences, MAY 20, 2019, View Source [SID1234536489]). The abstract was published on the EHA (Free EHA Whitepaper) website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: A Phase 2A Study of the LSD1 Inhibitor IMG-7289 For the Treatment of Myelofibrosis
Abstract Number: S832
Date: Saturday, June 15
Time: 12:30-12:45 CEST
Location: Elicium 2
The abstract represents the first report of clinical data on IMG-7289. The protocol of IMG-7289-CTP-102 is an ongoing Phase 1/2a clinical trial of LSD1 inhibitor IMG-7289 in patients with high or intermediate-2 risk myelofibrosis resistant to or intolerant of approved therapy (see clinicaltrials.gov NCT03136185).
In accordance with EHA (Free EHA Whitepaper) policies, abstracts submitted to the Annual Congress of EHA (Free EHA Whitepaper) are embargoed from the time of submission. The terms and conditions for presentation at the Annual Congress of EHA (Free EHA Whitepaper) prohibit any additional disclosure of data or information to be presented at the Annual Congress to be made public before the presentation.
Following the Annual Congress of EHA (Free EHA Whitepaper), a summary of the presentation will be available in the "News" section of Imago’s website.
About IMG-7289
IMG-7289 is a small molecule discovered by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme regulating cytokine expression and sustaining self-renewal in malignant hematopoietic stem/progenitor cells. In non-clinical studies, IMG-7289 demonstrated robust in vivo efficacy as a single agent and in combination with other therapeutic agents across a range of myeloid malignancies models including the myeloproliferative neoplasms which encompass myelofibrosis, essential thrombocythemia and polycythemia vera. IMG-7289 also shows activity against solid tumors in combination with other checkpoint agents in non-clinical models. IMG-7289 is under evaluation for the treatment of acute myeloid leukemia (see clinicaltrials.gov NCT02842827).